12th Jan 2015 08:52
LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that it expects to post revenue of around GBP28.2 million for its first half, up 4% from GBP27.2 million a year before, although hampered by the weakening euro.
The company said that at constant currency, revenue for its half year to end-December 2014 would be GBP30.2 million but were reduced by GBP2 million by conversion from the euro.
Allergy Therapeutics attributed its sales growth to its increasing market share in its main markets.
"Despite flat markets, we have been able to grow double digit at constant currency by increasing our market share, particularly in Germany and the Netherlands, thanks to our winning range of short-course aluminium-free allergy vaccines," said Chief Executive Officer Manuel Llobet in a statement.
Shares in Allergy Therapeutics are trading down 0.1% at 24.11 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.